Onkológia 1/2024
Decision-making algorithm in the therapy of patients with advanced malignant melanoma
Significant advances have been made in the treatment of advanced malignant melanoma with checkpoint inhibitors and targeted therapy with dual BRAF/MEK blockade. We have several options in first-line treatment. However, for many patients, deciding on first-line treatment is complicated. These include, in particular, patients with newly diagnosed disease, those resistant or refractory to treatment with immune checkpoint inhibitors, those with central nervous system metastases, a history of autoimmune disease, and/or immune-related adverse events.
Keywords: advanced malignant melanoma, immune checkpoint inhibitors, dual BRAF/MEK blockade
